entity,start_date,end_date,context,AARSRAPPORT_html,AARSRAPPORT_pdf,AARSRAPPORT_xml,AdditionsToInvestments,AddressOfAuditorDistrictName,AddressOfAuditorPostCodeIdentifier,AddressOfAuditorStreetBuildingIdentifier,AddressOfAuditorStreetName,AddressOfReportingEntityDistrictName,AddressOfReportingEntityPostCodeIdentifier,AddressOfReportingEntityStreetBuildingIdentifier,AddressOfReportingEntityStreetName,AddressOfSubmittingEnterprisePostcodeAndTown,AddressOfSubmittingEnterpriseStreetAndNumber,AddresseeOfAuditorsReportOnAuditedFinancialStatements,AdjustmentsForCurrentTaxOfPriorPeriod,AverageNumberOfEmployees,ClassOfReportingEntity,ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement,ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults,CurrentTaxExpense,DateOfApprovalOfAnnualReport,DateOfFoundationOfReportingEntity,DateOfGeneralMeeting,DepositsLongtermInvestmentsAndReceivables,DescriptionOfAnyUncertaintyConnectedWithRecognitionOrMeasurement,DescriptionOfAnyUnusualMattersAffectingRecognitionOrMeasurement,DescriptionOfAuditor,DescriptionOfDevelopmentInActivitiesAndFinancialAffairs,DescriptionOfExpectedDevelopment,DescriptionOfImpactOnExternalEnvironmentAndMeasuresOfPreventingReducingOrMitigatingDamage,DescriptionOfMethodsOfCurrentTaxReceivablesAndLiabilities,DescriptionOfMethodsOfDividends,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfDeferredIncomeAssets,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfEmployeeBenefitExpense,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncomeAndExpenses,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfOtherOperatingIncome,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfRevenue,DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses,DescriptionOfPrimaryActivitiesOfEntity,DescriptionOfQualificationsOfAuditedFinancialStatements,DescriptionOfResearchAndDevelopmentActivitiesInAndForReportingEntity,DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod,DisclosureOfAccountingPolicies,DisclosureOfEmployeeBenefitsExpense,DisclosureOfLiabilitiesUnderLeases,DividendPaid,EmployeeBenefitsExpense,ExchangeRateAdjustmentsOtherFinanceIncome,ExplanationOfNotDisclosingCashFlowsStatements,ExplanationOfPrepayments,FaxNumberOfReportingEntity,GrossResult,HomepageOfReportingEntity,IdentificationNumberCvrOfReportingEntity,IdentificationNumberCvrOfSubmittingEnterprise,IdentificationNumberOfAuditor,IdentificationOfApprovedAnnualReport,InformationOnReportingClassOfEntity,InformationOnTypeOfSubmittedReport,InterestIncomeFromGroupEnterprises,InvestmentsGross,ManagementsStatementAboutManagementsReview,NameAndSurnameOfAuditor,NameAndSurnameOfChairmanOfGeneralMeeting,NameAndSurnameOfMemberOfExecutiveBoard,NameOfFinancialInstitution,NameOfReportingEntity,NameOfSubmittingEnterprise,NoncurrentAssets,OtherEmployeeExpense,OtherExternalExpenses,OtherFinanceIncome,OtherOperatingIncome,PlaceOfSignatureOfStatement,PostemploymentBenefitExpense,PrecedingReportingPeriodStartDate,PredingReportingPeriodEndDate,ProfitLoss,ProfitLossAfterAttributableToMinorityInterest,ProfitLossFromOrdinaryActivitiesBeforeTax,ProfitLossFromOrdinaryOperatingActivities,RawMaterialsAndConsumablesUsed,RecommendationForApprovalOfAnnualReportByGeneralMeeting,RegisteredOfficeOfReportingEntity,ReportingPeriodEndDate,ReportingPeriodStartDate,RestOfOtherFinanceExpenses,Revenue,SignatureOfAuditorsDate,SignatureOfAuditorsPlace,SocialSecurityContributions,TaxExpenseOnOrdinaryActivities,TelephoneNumberOfReportingEntity,TitleOfMemberOfSupervisoryBoard,TypeOfAuditorAssistance,WagesAndSalaries,_id,_index,_score,cvrNummer,indlaesningsId,indlaesningsTidspunkt,offentliggoerelsesTidspunkt,offentliggoerelsestype,omgoerelse,regNummer,regnskabsperiode_slutDato,regnskabsperiode_startDato,sagsNummer,sidstOpdateret,Assets,CashAndCashEquivalents,ContributedCapital,CurrentAssets,DeferredIncomeAssets,Equity,LiabilitiesAndEquity,LiabilitiesOtherThanProvisions,LiabilitiesUnderLeasesIfDisclosedSeparately,OtherReceivables,OtherShorttermPayables,OtherShorttermReceivables,ProposedDividendRecognisedInEquity,RetainedEarnings,ShorttermLiabilitiesOtherThanProvisions,ShorttermPayablesToGroupEnterprises,ShorttermReceivables,ShorttermReceivablesFromGroupEnterprises,ShorttermTaxPayables,ShorttermTradePayables,ShorttermTradeReceivables,NameAndSurnameOfMemberOfSupervisoryBoard,RelatedEntityNameConsolidatedFinancialStatements,LongtermInvestmentsAndReceivables,NominalValueOfIssuedShares,NumberOfIssuedShares,DescriptionOfClassOfIssuedShares
20601116,2016-01-01,2016-12-31,D-2016,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,1168430.0,29.0,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",17228142.0,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,25548544.0,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,101018653.0,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,42590556.0,64046.0,33801014.0,Espoo,1963787.0,2016-01-01,2016-12-31,56727015.0,56727015.0,75123587.0,75470109.0,263847734.0,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,410568.0,373655929.0,2018-05-14,Copenhagen,295867.0,18396572.0,4586140000.0,Chairman,RevisionspÃ¥tegning,23288890.0,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-01-01,2016-12-31,D-2016-dim-GeografiskomrÃ¥de01-,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,370140344.0,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-01-01,2016-12-31,D-2016-dim-GeografiskomrÃ¥de03-,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,3515585.0,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-01-01,2016-12-31,D-2016-dim-ProposedDividendReco,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,40000000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-01-01,2016-12-31,D-2016-dim-ProposedDividendReco.1,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,40000000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-01-01,2016-12-31,D-2016-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,16727015.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-01-01,2016-12-31,D-2016-dim-RetainedEarningsMemb.1,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,16727015.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2016-12-31,2016-12-31,I-2016-E,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,162424998.0,941961.0,3000000.0,162424998.0,1499657.0,97341617.0,162424998.0,65083381.0,2313000.0,164112.0,8390808.0,164112.0,40000000.0,54341617.0,65083381.0,35423121.0,161483037.0,63079314.0,12196142.0,9073310.0,96739954.0,,,,,,
20601116,2016-12-31,2016-12-31,I-2016-E-dim-ContributedCapitalMe,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,3000000.0,,,,,,,,,,,,,,,,,,,,,
20601116,2016-12-31,2016-12-31,I-2016-E-dim-ProposedDividendReco,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,40000000.0,,,,,,,,,,,,,,,,,,,,,
20601116,2016-12-31,2016-12-31,I-2016-E-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,54341617.0,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,-183789.0,29.0,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",11750437.0,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,23186292.0,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,73018412.0,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,43169056.0,64046.0,30376173.0,Espoo,1886413.0,2016-01-01,2016-12-31,37821319.0,37821319.0,49387967.0,49832120.0,241926689.0,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,444153.0,327737984.0,2018-05-14,Copenhagen,243789.0,11566648.0,4586140000.0,Chairman,RevisionspÃ¥tegning,20969175.0,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-Bestyrelsesmedlem1,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,Satu AhomÃ¤ki,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-Bestyrelsesmedlem2,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,Olli Heikki Huotari,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-Bestyrelsesmedlem3,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,Jari Ilmari Karlson,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-DepositsLongtermInve,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-Direktionsmedlem01,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-FourYearsAgoMember,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,25585000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-GeografiskomrÃ¥de01-,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,324042889.0,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-GeografiskomrÃ¥de03-,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,3695095.0,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-ParentOfLargestGroup,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,"Orion Corporation, Finland",,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-ParentOfSmallestGrou,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,"Orion Corporation, Finland",,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-ProposedDividendReco,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,65000000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-ProposedDividendReco.1,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,65000000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,-27178681.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-RetainedEarningsMemb.1,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,-27178681.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-Revisionsvirksomhed0.1,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-ThreeYearsAgoMember,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,24676000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-01-01,2017-12-31,D-2017-dim-TwoYearsAgoMember,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,44822000.0,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,,,
20601116,2017-12-31,2017-12-31,I-2017-E,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,131550542.0,3706648.0,3000000.0,131371642.0,1405137.0,95162936.0,131550542.0,36387606.0,2006000.0,1123.0,7213889.0,1123.0,65000000.0,27162936.0,36387606.0,19076646.0,127664994.0,76990984.0,5706437.0,4390634.0,49267750.0,,,178900.0,3000000.0,251.0,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-ContributedCapitalMe,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,3000000.0,,,,,,,,,,,,,,,,,,,,,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-DepositsLongtermInve,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,178900.0,,,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-FourYearsAgoMember,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,72363000.0,,,,,39117000.0,,,,,,,,,,,,,,,,,,,,,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse01,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,2100000.0,21.0,Shares
20601116,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse02,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,750000.0,75.0,Shares
20601116,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse03,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,10000.0,2.0,Shares
20601116,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse04,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,135000.0,135.0,Shares
20601116,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse05,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,4000.0,8.0,Shares
20601116,2017-12-31,2017-12-31,I-2017-E-dim-Kapitalklasse06,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,,,,,,,,,,,,,,,,,,,,1000.0,10.0,Shares
20601116,2017-12-31,2017-12-31,I-2017-E-dim-ProposedDividendReco,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,65000000.0,,,,,,,,,,,,,,,,,,,,,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-RetainedEarningsMemb,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,,,,,,27162936.0,,,,,,,,,,,,,,,,,,,,,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-ThreeYearsAgoMember,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,76264000.0,,,,,46793000.0,,,,,,,,,,,,,,,,,,,,,
20601116,2017-12-31,2017-12-31,I-2017-E-dim-TwoYearsAgoMember,,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzEwLzY5LzlmLzM4L2QxNmQtNDM3ZC1hM2UwLWI3NDU2NzljMTYxNQ.pdf,http://regnskaber.virk.dk/61110602/ZG9rdW1lbnRsYWdlcjovLzAzLzVkLzY2LzI5LzU1L2U0YmYtNGNjYy1hMTFmLTIwMzRmZTE4YTI0OQ.xml,178900.0,Hellerup,2900.0,44.0,Strandvejen,KÃ¸benhavn S,2300.0,73.0,Ãrestads Boulevard,0900 KÃ¸benhavn C,Weidekampsgade Postboks 1600,To the shareholders of Orion Pharma A/S,,,"Regnskabsklasse C, mellemstor virksomhed",The annual report is presented in accordance with the Danish Financial Statements Act.,"In our opinion, the financial statements give a true and fair view of the Entityâs financial position at 31.12.2017 and of the results of its operations for the financial year 01.01.2017 - 31.12.2017.",,2018-04-24,1953-02-16,2018-05-14,178900.0,Recognition and measurement in the annual report have not been subject to any uncertainty.,The financial position at 31 December 2017 of the Company and the results of the activities of the Company for the financial year for 2017 have not been affected by any unusual events.,State Authorised Public Accountant,The income statement of the Company for 2017 show a profit of DKK 37.8 million and at 31 December 2017 the balance sheet of the Company shows equity of DKK 95.2 million.,"The sales in 2018 of pharmaceutical products is expected to be at the same level as in 2017. For the 2018 as a whole, there is expected a positive result.","The overall environmental goal of Orion Pharma A/S is to carry out activities in consideration of the employees, the working environment and the surroundings, with the objective of maintaining a safe, healthy and sound environment, both externally and internally.","Current tax payable or receivable is recognised in the balance sheet, stated as tax computed on this year's taxable income, adjusted for prepaid tax",Dividend is recognised as a liability at the time of adoption at the general meeting. Proposed dividend for the financial year is disclosed as a separate item in equity. Extraordinary dividend adopted in the financial year is recognised directly in equity when distributed and disclosed as a separate item in Management's proposal for distribution of profit/loss.,Cash comprises cash in hand and bank deposits.,Prepayments comprise incurred costs relating to subsequent financial years. Prepayments are measured at cost.,"Staff costs comprise salaries and wages as well as social security contributions, pension contributions, etc for entity staff.","Costs of raw materials and consumables comprise the consumption of raw materials and consumables for the financial year after adjustment for changes in inventories of these goods from the beginning to the end of the year. This item includes shrinkage, if any, and ordinary writedowns of the relevant inventories. Other external expenses include expenses relating to the Entityâs ordinary activities, including expenses for premises, stationery and office supplies, marketing costs, etc. This item also includes writedowns of receivables recognised in current assets.","Other financial income comprises interest income, including interest income on receivables from group enterprises, payables and transactions in foreign currencies. Other financial expenses comprise interest expenses, including interest expenses on payables to group enterprises, transactions in foreign currencies, and tax relief under the Danish Tax prepayment Scheme etc.","Other financial liabilities are measured at amortised cost, which usually corresponds to nominal value.","Other operating income comprises income of a secondary nature as viewed in relation to the Entityâs primary activities, including rental income and gains from the sale of intangible assets and property, plant and equipment.","Receivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and doubtful debts.","Revenue from the sale of manufactured goods and goods for resale is recognised in the income statement when delivery is made and risk has passed to the buyer. Revenue is recognised net of VAT, duties and sales discounts and is measured at fair value of the consideration fixed.","Tax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the income statement by the portion attributable to the profit for the year and recognised directly in equity by the portion attributable to entries directly in equity.",The Primary activities of Orion Pharma A/S are sales of generic and original pharmaceutical products.,"We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the Auditorâs Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountantsâ Code of Ethics for Professional Accountants (IESBA Code) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.",Orion Pharma A/S did not conduct any independent research and development activities in 2017.,"No events have occurred after the balance sheet date to this date, which would influence the evaluation of this annual report.",The accounting policies applied to these financial statements are consistent with those applied last year.,Remuneration to the Executive Board has not been disclosed in accordance with section 98 B(3) of the Danish Financial Statement Act.,Leasing obligations under operating leases - payment within one year DKK 1.159.000 (2016: DKK 1.279.000).,-40000000.0,,5490.0,"With reference to section 86(4) of the Danish Financial Statements Act, no cash flow statement for the parent company is prepared, as the parent companyâs cash flows are part of the consolidated cash flow statement.",Prepayments comprise prepaid expenses regarding subsequent financial reporting years.,4586140001.0,,www.orionpharma.dk,20601116.0,33963556.0,mne18651,The Board of Directors and the Executive Board have today considered and approved the annual report of Orion Pharma A/S for the financial year 01.01.2017 - 31.12.2017.,This annual report has been presented in accordance with the provisions of the Danish Financial Statements Act governing reporting class C enterprises (medium-size).,Ãrsrapport,58556.0,178900.0,We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.,Torben Jensen,Jesper Quist-Pedersen,Jesper Otto Qvist-Pedersen,Danske Bank A/S,Orion Pharma A/S,Deloitte Statsautoriseret Revisionspartnerselskab,178900.0,86915.0,,64046.0,,Espoo,,2016-01-01,2016-12-31,,,,,,We recommend the annual report for adoption at the Annual General Meeting.,Copenhagen,2017-12-31,2017-01-01,,,2018-05-14,Copenhagen,,,4586140000.0,Chairman,RevisionspÃ¥tegning,,urn:ofk:oid:25554329,indberetninger-20180424,2.5118417999999996,20601116.0,AWOiVuVzx8uVRSOdg4Di,2018-05-27T16:03:27.733Z,2018-05-27T16:03:13.308Z,regnskab,0.0,,2017-12-31,2017-01-01,X18-AM-70-VG,2018-05-27T16:03:13.469Z,122350000.0,,,,,66615000.0,,,,,,,,,,,,,,,,,,,,,
